1
|
Lindqvist HM, Gjertsson I, Hulander E, Bärebring L, Winkvist A. Exploring the differences in serum metabolite profiles after intake of red meat in women with rheumatoid arthritis and a matched control group. Eur J Nutr 2024; 63:221-230. [PMID: 37814020 PMCID: PMC10798910 DOI: 10.1007/s00394-023-03257-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2023] [Accepted: 09/15/2023] [Indexed: 10/11/2023]
Abstract
PURPOSE Studies have suggested that women with RA tend to avoid red meat more often than women without RA, based on their perception that it exacerbates their symptoms. Therefore, the aim of this study is to investigate and compare the postprandial metabolic response following the consumption of a red meat meal in patients with RA and a matched control group. METHODS Participants were challenged with a meal with red meat and blood samples were collected before and at 0.5, 1, 2, 3 and 5 h after the meal. Serum metabolites were quantified by Nuclear Magnetic Resonance (NMR) analysis. Orthogonal Projections to Latent Structures with Discriminant Analysis (OPLS-DA) was used to evaluate separation by metabolites due to diagnosis of RA or not and to identify changes in metabolites related to RA. Incremental area under the curve was calculated for univariate comparisons for 23 metabolites. RESULTS The matched groups, including 22 women with RA and 22 women without RA, did not differ significantly in age, body mass index, diet quality or reported physical activity. OPLS-DA models had a limited quality indicating that there were no differences in metabolite patterns between the groups. However, phenylalanine was significantly higher in concentration in women with RA compared to controls in both fasting and postprandial samples. CONCLUSION To conclude, this well-controlled postprandial intervention study found a significantly higher concentration of phenylalanine in both fasting and postprandial samples of women with RA compared to matched women without RA. These findings warrant further investigation in larger studies. TRIAL REGISTRATION The PIRA (Postprandial Inflammation in Rheumatoid Arthritis) trial is Registered at Clinicaltrials.gov (NCT04247009).
Collapse
Affiliation(s)
- Helen M Lindqvist
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
| | - Inger Gjertsson
- Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Erik Hulander
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Linnea Bärebring
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Anna Winkvist
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
2
|
Wang S, Niu Y, Zhang H, Zhao Z, Zhang X. Metabolomic alterations in healthy adults traveling to low-pollution areas: A natural experiment with ozone exposure. THE SCIENCE OF THE TOTAL ENVIRONMENT 2023; 897:165501. [PMID: 37442463 DOI: 10.1016/j.scitotenv.2023.165501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Revised: 07/05/2023] [Accepted: 07/10/2023] [Indexed: 07/15/2023]
Abstract
Numerous epidemiological studies have demonstrated links between short-term ozone exposure to various adverse health outcomes, but some ozone-induced pathological mechanisms remain unclear. To fill this knowledge gap, we enrolled 36 healthy young adults living in high-ozone areas and performed an untargeted metabolomic analysis in serum collected before, during, and after their travel to a low-ozone scenic area. Reviewing the literature, we found 16 metabolites significantly associated with ozone, pointing to neurological health, type 2 diabetes (T2D) risk, and cardiovascular health. Notably, we observed significant changes in these 16 metabolites from the ozone reduction when participants traveled from the campus to the scenic area (adjusted p-value < 0.05). However, when ozone increased after participants returned to campus from the scenic area, we observed that T2D risk and cardiovascular health-related metabolites returned to their original state (adjusted p-value < 0.05), but neurological health-related metabolites did not change significantly with ozone exposure. Our study showed that ozone exposure was linked to prompt alterations in serum metabolites related to cardiovascular health and T2D risk but less sensitive changes in neurological health-related metabolites. Among many lipids, free fatty acids and acylcarnitines were the most sensitive compounds positively associated with changes in ozone exposure.
Collapse
Affiliation(s)
- Shengchun Wang
- Institute of Environmental Science, Shanxi University, Taiyuan 030006, China
| | - Yue Niu
- Department of Environmental Health, School of Public Health, Fudan University, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Shanghai 200032, China
| | - Huilin Zhang
- Institute of Environmental Science, Shanxi University, Taiyuan 030006, China
| | - Zhuohui Zhao
- Department of Environmental Health, School of Public Health, Fudan University, Key Lab of Public Health Safety of the Ministry of Education and NHC Key Lab of Health Technology Assessment, Shanghai 200032, China.
| | - Xin Zhang
- Institute of Environmental Science, Shanxi University, Taiyuan 030006, China.
| |
Collapse
|
3
|
Barsch L, Werdehausen R, Leffler A, Eulenburg V. Modulation of Glycinergic Neurotransmission may Contribute to the Analgesic Effects of Propacetamol. Biomolecules 2021; 11:biom11040493. [PMID: 33805979 PMCID: PMC8064320 DOI: 10.3390/biom11040493] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 03/20/2021] [Accepted: 03/22/2021] [Indexed: 11/25/2022] Open
Abstract
Treating neuropathic pain remains challenging, and therefore new pharmacological strategies are urgently required. Here, the enhancement of glycinergic neurotransmission by either facilitating glycine receptors (GlyR) or inhibiting glycine transporter (GlyT) function to increase extracellular glycine concentration appears promising. Propacetamol is a N,N-diethylester of acetaminophen, a non-opioid analgesic used to treat mild pain conditions. In vivo, it is hydrolysed into N,N-diethylglycine (DEG) and acetaminophen. DEG has structural similarities to known alternative GlyT1 substrates. In this study, we analyzed possible effects of propacetamol, or its metabolite N,N-diethylglycine (DEG), on GlyRs or GlyTs function by using a two-electrode voltage clamp approach in Xenopus laevis oocytes. Our data demonstrate that, although propacetamol or acetaminophen had no effect on the function of the analysed glycine-responsive proteins, the propacetamol metabolite DEG acted as a low-affine substrate for both GlyT1 (EC50 > 7.6 mM) and GlyT2 (EC50 > 5.2 mM). It also acted as a mild positive allosteric modulator of GlyRα1 function at intermediate concentrations. Taken together, our data show that DEG influences both glycine transporter and receptor function, and therefore could facilitate glycinergic neurotransmission in a multimodal manner.
Collapse
Affiliation(s)
- Lukas Barsch
- Department of Anaesthesiology and Intensive Care, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany; (L.B.); (R.W.)
| | - Robert Werdehausen
- Department of Anaesthesiology and Intensive Care, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany; (L.B.); (R.W.)
| | - Andreas Leffler
- Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, 30625 Hannover, Germany;
| | - Volker Eulenburg
- Department of Anaesthesiology and Intensive Care, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany; (L.B.); (R.W.)
- Correspondence: ; Tel.: +49-341-9710598
| |
Collapse
|
4
|
Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. Int J Mol Sci 2021; 22:ijms22052479. [PMID: 33804568 PMCID: PMC7957511 DOI: 10.3390/ijms22052479] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 02/19/2021] [Accepted: 02/25/2021] [Indexed: 12/16/2022] Open
Abstract
The limited effect of current medications on neuropathic pain (NP) has initiated large efforts to develop effective treatments. Animal studies showed that glycine transporter (GlyT) inhibitors are promising analgesics in NP, though concerns regarding adverse effects were raised. We aimed to study NFPS and Org-25543, GlyT-1 and GlyT-2 inhibitors, respectively and their combination in rat mononeuropathic pain evoked by partial sciatic nerve ligation. Cerebrospinal fluid (CSF) glycine content was also determined by capillary electrophoresis. Subcutaneous (s.c.) 4 mg/kg NFPS or Org-25543 showed analgesia following acute administration (30-60 min). Small doses of each compound failed to produce antiallodynia up to 180 min after the acute administration. However, NFPS (1 mg/kg) produced antiallodynia after four days of treatment. Co-treatment with subanalgesic doses of NFPS (1 mg/kg) and Org-25543 (2 mg/kg) produced analgesia at 60 min and thereafter meanwhile increased significantly the CSF glycine content. This combination alleviated NP without affecting motor function. Test compounds failed to activate G-proteins in spinal cord. To the best of our knowledge for the first time we demonstrated augmented analgesia by combining GlyT-1 and 2 inhibitors. Increased CSF glycine content supports involvement of glycinergic system. Combining selective GlyT inhibitors or developing non-selective GlyT inhibitors might have therapeutic value in NP.
Collapse
|
5
|
Al-Khrasani M, Mohammadzadeh A, Balogh M, Király K, Barsi S, Hajnal B, Köles L, Zádori ZS, Harsing LG. Glycine transporter inhibitors: A new avenue for managing neuropathic pain. Brain Res Bull 2019; 152:143-158. [PMID: 31302238 DOI: 10.1016/j.brainresbull.2019.07.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 06/27/2019] [Accepted: 07/08/2019] [Indexed: 12/12/2022]
Abstract
Interneurons operating with glycine neurotransmitter are involved in the regulation of pain transmission in the dorsal horn of the spinal cord. In addition to interneurons, glycine release also occurs from glial cells neighboring glutamatergic synapses in the spinal cord. Neuronal and glial release of glycine is controlled by glycine transporters (GlyTs). Inhibitors of the two isoforms of GlyTs, the astrocytic type-1 (GlyT-1) and the neuronal type-2 (GlyT-2), decrease pain sensation evoked by injuries of peripheral sensory neurons or inflammation. The function of dorsal horn glycinergic interneurons has been suggested to be reduced in neuropathic pain, which can be reversed by GlyT-2 inhibitors (Org-25543, ALX1393). Several lines of evidence also support that peripheral nerve damage or inflammation may shift glutamatergic neurochemical transmission from N-methyl-D aspartate (NMDA) NR1/NR2A receptor- to NR1/NR2B receptor-mediated events (subunit switch). This pathological overactivation of NR1/NR2B receptors can be reduced by GlyT-1 inhibitors (NFPS, Org-25935), which decrease excessive glycine release from astroglial cells or by selective antagonists of NR2B subunits (ifenprodil, Ro 25-6981). Although several experiments suggest that GlyT inhibitors may represent a novel strategy in the control of neuropathic pain, proving this concept in human beings is hampered by lack of clinically applicable GlyT inhibitors. We also suggest that drugs inhibiting both GlyT-1 and GlyT-2 non-selectively and reversibly, may favorably target neuropathic pain. In this paper we overview inhibitors of the two isoforms of GlyTs as well as the effects of these drugs in experimental models of neuropathic pain. In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.
Collapse
Affiliation(s)
- Mahmoud Al-Khrasani
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary.
| | - Amir Mohammadzadeh
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - Mihály Balogh
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - Kornél Király
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - Szilvia Barsi
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - Benjamin Hajnal
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - László Köles
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - Zoltán S Zádori
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| | - Laszlo G Harsing
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvarad ter 4, P.O. Box 370, H-1445 Budapest, Hungary
| |
Collapse
|
6
|
Cioffi CL, Liu S, Wolf MA, Guzzo PR, Sadalapure K, Parthasarathy V, Loong DTJ, Maeng JH, Carulli E, Fang X, Karunakaran K, Matta L, Choo SH, Panduga S, Buckle RN, Davis RN, Sakwa SA, Gupta P, Sargent BJ, Moore NA, Luche MM, Carr GJ, Khmelnitsky YL, Ismail J, Chung M, Bai M, Leong WY, Sachdev N, Swaminathan S, Mhyre AJ. Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1. J Med Chem 2016; 59:8473-94. [PMID: 27559615 DOI: 10.1021/acs.jmedchem.6b00914] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
We previously disclosed the discovery of rationally designed N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1 (GlyT-1), represented by analogues 10 and 11. We describe herein further structure-activity relationship exploration of this series via an optimization strategy that primarily focused on the sulfonamide and benzamide appendages of the scaffold. These efforts led to the identification of advanced leads possessing a desirable balance of excellent in vitro GlyT-1 potency and selectivity, favorable ADME and in vitro pharmacological profiles, and suitable pharmacokinetic and safety characteristics. Representative analogue (+)-67 exhibited robust in vivo activity in the cerebral spinal fluid glycine biomarker model in both rodents and nonhuman primates. Furthermore, rodent microdialysis experiments also demonstrated that oral administration of (+)-67 significantly elevated extracellular glycine levels within the medial prefrontal cortex (mPFC).
Collapse
Affiliation(s)
- Christopher L Cioffi
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Shuang Liu
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Mark A Wolf
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Peter R Guzzo
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Kashinath Sadalapure
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Visweswaran Parthasarathy
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - David T J Loong
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Jun-Ho Maeng
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Edmund Carulli
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Xiao Fang
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Kalesh Karunakaran
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Lakshman Matta
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Sok Hui Choo
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Shailijia Panduga
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Ronald N Buckle
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Randall N Davis
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Samuel A Sakwa
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Priya Gupta
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Bruce J Sargent
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Nicholas A Moore
- Department of Medicinal Chemistry, AMRI , East Campus, 3 University Place, Rensselaer, New York 12144, United States
| | - Michele M Luche
- Bothell Research Center, AMRI , 22215 26th Ave SE, Bothell, Washington 98021-4425, United States
| | - Grant J Carr
- Bothell Research Center, AMRI , 22215 26th Ave SE, Bothell, Washington 98021-4425, United States
| | - Yuri L Khmelnitsky
- Drug Metabolism and Pharmacokinetics, AMRI , East Campus, 17 University Place, Rensselaer, New York 12144, United States
| | - Jiffry Ismail
- Drug Metabolism and Pharmacokinetics, AMRI , East Campus, 17 University Place, Rensselaer, New York 12144, United States
| | - Mark Chung
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Mei Bai
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Wei Yee Leong
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Nidhi Sachdev
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Srividya Swaminathan
- Discovery Research and Development Chemistry, Singapore Research Center, AMRI , 61 Science Park Road, Science Park III, 117525, Singapore
| | - Andrew J Mhyre
- Bothell Research Center, AMRI , 22215 26th Ave SE, Bothell, Washington 98021-4425, United States
| |
Collapse
|
7
|
The lidocaine metabolite N-ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain. Pain 2016; 156:1647-1659. [PMID: 25932687 PMCID: PMC4617288 DOI: 10.1097/j.pain.0000000000000206] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Supplemental Digital Content is Available in the Text. The lidocaine metabolite N-ethylglycine specifically reduces GlyT1-dependent glycine uptake and has antinociceptive effects in experimental inflammatory and neuropathic pain, while no adverse effects are observed. Glycine transporter 1 (GlyT1) plays a crucial role in regulating extracellular glycine concentrations and might thereby constitute a new drug target for the modulation of glycinergic inhibition in pain signaling. Consistent with this view, inhibition of GlyT1 has been found to induce antinociceptive effects in various animal pain models. We have shown previously that the lidocaine metabolite N-ethylglycine (EG) reduces GlyT1-dependent glycine uptake by functioning as an artificial substrate for this transporter. Here, we show that EG is specific for GlyT1 and that in rodent models of inflammatory and neuropathic pain, systemic treatment with EG results in an efficient amelioration of hyperalgesia and allodynia without affecting acute pain. There was no effect on motor coordination or the development of inflammatory edema. No adverse neurological effects were observed after repeated high-dose application of EG. EG concentrations both in blood and spinal fluid correlated with an increase of glycine concentration in spinal fluid. The time courses of the EG and glycine concentrations corresponded well with the antinociceptive effect. Additionally, we found that EG reduced the increase in neuronal firing of wide-dynamic-range neurons caused by inflammatory pain induction. These findings suggest that systemically applied lidocaine exerts antihyperalgesic effects through its metabolite EG in vivo, by enhancing spinal inhibition of pain processing through GlyT1 modulation and subsequent increase of glycine concentrations at glycinergic inhibitory synapses. EG and other substrates of GlyT1, therefore, may be a useful therapeutic agent in chronic pain states involving spinal disinhibition.
Collapse
|
8
|
Vachon-Presseau E, Centeno MV, Ren W, Berger SE, Tétreault P, Ghantous M, Baria A, Farmer M, Baliki MN, Schnitzer TJ, Apkarian AV. The Emotional Brain as a Predictor and Amplifier of Chronic Pain. J Dent Res 2016; 95:605-12. [PMID: 26965423 DOI: 10.1177/0022034516638027] [Citation(s) in RCA: 129] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Human neuroimaging studies and complementary animal experiments now identify the gross elements of the brain involved in the chronification of pain. We briefly review these advances in relation to somatic and orofacial persistent pain conditions. First, we emphasize the importance of reverse translational research for understanding chronic pain-that is, the power of deriving hypotheses directly from human brain imaging of clinical conditions that can be invasively and mechanistically studied in animal models. We then review recent findings demonstrating the importance of the emotional brain (i.e., the corticolimbic system) in the modulation of acute pain and in the prediction and amplification of chronic pain, contrasting this evidence with recent findings regarding the role of central sensitization in pain chronification, especially for orofacial pain. We next elaborate on the corticolimbic circuitry and underlying mechanisms that determine the transition to chronic pain. Given this knowledge, we advance a new mechanistic definition of chronic pain and discuss the clinical implications of this new definition as well as novel therapeutic potentials suggested by these advances.
Collapse
Affiliation(s)
- E Vachon-Presseau
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - M V Centeno
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - W Ren
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - S E Berger
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - P Tétreault
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - M Ghantous
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - A Baria
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - M Farmer
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - M N Baliki
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - T J Schnitzer
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - A V Apkarian
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| |
Collapse
|
9
|
Abstract
Recent neuroimaging studies suggest that the brain adapts with pain, as well as imparts risk for developing chronic pain. Within this context, we revisit the concepts for nociception, acute and chronic pain, and negative moods relative to behavior selection. We redefine nociception as the mechanism protecting the organism from injury, while acute pain as failure of avoidant behavior, and a mesolimbic threshold process that gates the transformation of nociceptive activity to conscious pain. Adaptations in this threshold process are envisioned to be critical for development of chronic pain. We deconstruct chronic pain into four distinct phases, each with specific mechanisms, and outline current state of knowledge regarding these mechanisms: the limbic brain imparting risk, and the mesolimbic learning processes reorganizing the neocortex into a chronic pain state. Moreover, pain and negative moods are envisioned as a continuum of aversive behavioral learning, which enhance survival by protecting against threats.
Collapse
Affiliation(s)
- Marwan N Baliki
- Department of Physiology, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60610, USA.
| | - A Vania Apkarian
- Department of Physiology, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60610, USA; Department of Anesthesia, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60610, USA; Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60610, USA.
| |
Collapse
|
10
|
Alvarado S, Tajerian M, Suderman M, Machnes Z, Pierfelice S, Millecamps M, Stone LS, Szyf M. An epigenetic hypothesis for the genomic memory of pain. Front Cell Neurosci 2015; 9:88. [PMID: 25852480 PMCID: PMC4371710 DOI: 10.3389/fncel.2015.00088] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Accepted: 02/26/2015] [Indexed: 11/13/2022] Open
Abstract
Chronic pain is accompanied with long-term sensory, affective and cognitive disturbances. What are the mechanisms that mediate the long-term consequences of painful experiences and embed them in the genome? We hypothesize that alterations in DNA methylation, an enzymatic covalent modification of cytosine bases in DNA, serve as a "genomic" memory of pain in the adult cortex. DNA methylation is an epigenetic mechanism for long-term regulation of gene expression. Neuronal plasticity at the neuroanatomical, functional, morphological, physiological and molecular levels has been demonstrated throughout the neuroaxis in response to persistent pain, including in the adult prefrontal cortex (PFC). We have previously reported widespread changes in gene expression and DNA methylation in the PFC many months following peripheral nerve injury. In support of this hypothesis, we show here that up-regulation of a gene involved with synaptic function, Synaptotagmin II (syt2), in the PFC in a chronic pain model is associated with long-term changes in DNA methylation. The challenges of understanding the contributions of epigenetic mechanisms such as DNA methylation within the PFC to pain chronicity and their therapeutic implications are discussed.
Collapse
Affiliation(s)
- Sebastian Alvarado
- Department of Biology, Stanford University Palo Alto, CA, USA ; Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University Montréal, QC, Canada ; Sackler Program for Epigenetics and Developmental Psychobiology, McGill University Montréal, QC, Canada
| | - Maral Tajerian
- Department of Anesthesiology, Stanford University Palo Alto, CA, USA ; Integrated Program in Neuroscience, McGill University Montréal, QC, Canada ; Alan Edwards Centre for Research on Pain, McGill University Montréal, QC, Canada
| | - Matthew Suderman
- Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University Montréal, QC, Canada ; Sackler Program for Epigenetics and Developmental Psychobiology, McGill University Montréal, QC, Canada
| | - Ziv Machnes
- Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University Montréal, QC, Canada ; Sackler Program for Epigenetics and Developmental Psychobiology, McGill University Montréal, QC, Canada
| | - Stephanie Pierfelice
- Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University Montréal, QC, Canada ; Sackler Program for Epigenetics and Developmental Psychobiology, McGill University Montréal, QC, Canada
| | - Magali Millecamps
- Alan Edwards Centre for Research on Pain, McGill University Montréal, QC, Canada ; Faculty of Dentistry, McGill University Montréal, QC, Canada
| | - Laura S Stone
- Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University Montréal, QC, Canada ; Integrated Program in Neuroscience, McGill University Montréal, QC, Canada ; Alan Edwards Centre for Research on Pain, McGill University Montréal, QC, Canada ; Faculty of Dentistry, McGill University Montréal, QC, Canada ; Department of Anesthesiology, Anesthesia Research Unit, Faculty of Medicine, McGill University Montréal, QC, Canada
| | - Moshe Szyf
- Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University Montréal, QC, Canada ; Sackler Program for Epigenetics and Developmental Psychobiology, McGill University Montréal, QC, Canada ; Integrated Program in Neuroscience, McGill University Montréal, QC, Canada
| |
Collapse
|
11
|
Takahashi Y, Hara K, Haranishi Y, Terada T, Obara G, Sata T. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav 2015; 130:46-52. [PMID: 25579325 DOI: 10.1016/j.pbb.2015.01.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Revised: 12/28/2014] [Accepted: 01/02/2015] [Indexed: 11/18/2022]
Abstract
Glycinergic transmission has an important role in regulating nociception in the spinal cord. The glycine transporter-2 (GlyT2) is localized at presynaptic terminals of glycinergic neurons and eliminates glycine from the synaptic cleft to terminate glycinergic transmission. Systemic and intrathecal administration of GlyT2 inhibitors alleviate various types of pain. Although the GlyT2s and glycine receptors are widely distributed in the central nervous system, little is known about the role of glycinergic transmission in pain perception at supraspinal regions. The present study examined the antinociceptive effect of intracerebroventricular (i.c.v.) administration of the selective GlyT2 inhibitor ALX1393 on inflammatory and neuropathic pain in experimental models. For i.c.v. administration, a guide cannula was implanted into the right lateral ventricle of male Sprague-Dawley rats. Normal rats were used to assess inflammatory nociception using the formalin test and motor function using the rotarod test. Chronic constriction injury (CCI) to the sciatic nerve was induced in the rats. The CCI rats were then used to assess mechanical, cold, and thermal hyperalgesia using the electronic von Frey test, cold plate test, and the plantar test, respectively. ALX1393 (25, 50, and 100 μg) was administered i.c.v. to examine its effects on supraspinal antinociception. Supraspinal ALX1393 in normal rats suppressed the late-phase response in the formalin test but did not affect motor performance. In the CCI rats, ALX1393 inhibited mechanical and cold hyperalgesia in a dose-dependent manner. The antihyperalgesic effects of ALX1393 (100 μg) were reversed completely by i.c.v. pretreatment with a glycine receptor antagonist strychnine (10 μg). These results suggest that GlyT2 contributes to nociceptive transmission at supraspinal level and that the selective GlyT2 inhibitor is a promising candidate for the treatment of inflammatory and neuropathic pain without causing motor dysfunction.
Collapse
Affiliation(s)
- Yoshihiro Takahashi
- Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Koji Hara
- Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | - Yasunori Haranishi
- Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Tadanori Terada
- Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Goh Obara
- Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Takeyoshi Sata
- Department of Anesthesiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| |
Collapse
|
12
|
Mansour AR, Farmer MA, Baliki MN, Apkarian AV. Chronic pain: the role of learning and brain plasticity. Restor Neurol Neurosci 2014; 32:129-39. [PMID: 23603439 DOI: 10.3233/rnn-139003] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Based on theoretical considerations and recent observations, we argue that continued suffering of chronic pain is critically dependent on the state of motivational and emotional mesolimbic-prefrontal circuitry of the brain. The plastic changes that occur within this circuitry in relation to nociceptive inputs dictate the transition to chronic pain, rendering the pain less somatic and more affective in nature. This theoretical construct is a strong departure from the traditional scientific view of pain, which has focused on encoding and representation of nociceptive signals. We argue that the definition of chronic pain can be recast, within the associative learning and valuation concept, as an inability to extinguish the associated memory trace, implying that supraspinal/cortical manipulations may be a more fruitful venue for adequately modulating suffering and related behavior for chronic pain. We briefly review the evidence generated to date for the proposed model and emphasize that the details of underlying mechanisms remain to be expounded.
Collapse
Affiliation(s)
- A R Mansour
- Department of Physiology, Surgery, and Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - M A Farmer
- Department of Physiology, Surgery, and Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - M N Baliki
- Department of Physiology, Surgery, and Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - A Vania Apkarian
- Department of Physiology, Surgery, and Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois Department of Anesthesia, Surgery, and Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| |
Collapse
|
13
|
Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats. Anesthesiology 2014; 121:160-9. [PMID: 24598217 DOI: 10.1097/aln.0000000000000203] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Dysfunction of spinal glycinergic neurotransmission is a major pathogenetic factor in neuropathic pain. The synaptic glycine concentration is controlled by the two glycine transporters (GlyT) 1 and 2. GlyT inhibitors act antinociceptive in various animal pain models when applied as bolus. Yet, in some studies, severe neuromotor side effects were reported. The aim of the current study was to elucidate whether continuous inhibition of GlyT ameliorates neuropathic pain without side effects and whether protein expression of GlyT1, GlyT2, or N-methyl-D-aspartate receptor subunit NR-1 in the spinal cord is affected. METHODS In the chronic constriction injury model of neuropathic pain, male Wistar rats received specific GlyT1 and GlyT2 inhibitors (ALX5407 and ALX1393; Sigma-Aldrich, St. Louis, MO) or vehicle for 14 days via subcutaneous osmotic infusion pumps (n = 6). Mechanical allodynia and thermal hyperalgesia were assessed before, after chronic constriction injury, and every 2 days during substance application. At the end of behavioral assessment, the expression of GlyT1, GlyT2, and NR-1 in the spinal cord was determined by Western blot analysis. RESULTS Both ALX5407 and ALX1393 ameliorated thermal hyperalgesia and mechanical allodynia in a time- and dose-dependent manner. Respiratory or neuromotor side effects were not observed. NR-1 expression in the ipsilateral spinal cord was significantly reduced by ALX5407, but not by ALX1393. The expression of GlyT1 and GlyT2 remained unchanged. CONCLUSIONS Continuous systemic inhibition of GlyT significantly ameliorates neuropathic pain in rats. Thus, GlyT represent promising targets in pain research. Modulation of N-methyl-D-aspartate receptor expression might represent a novel mechanism for the antinociceptive action of GyT1 inhibitors.
Collapse
|
14
|
Abstract
PURPOSE OF REVIEW Most individuals who develop pain following an inciting event will return to a healthy state as the injury heals. However, a small percentage continue to suffer, that is, transition to chronic pain. Chronic pain may persist for years and is accompanied by cognitive abnormalities, as well as diminished quality of life. In animals, persistent pain is characterized by peripheral and spinal cord reorganization, and recent evidence in humans also indicates cortical reorganization. Yet, despite more than 30 years of research, there is little agreement on the neural mechanisms that mediate the transition from acute to chronic pain. RECENT FINDINGS In a longitudinal brain-imaging study, individuals who developed an intense back pain episode were followed over a 1-year period, during which pain and brain parameters were collected repeatedly. A smaller number of healthy individuals and chronic back pain patients were also studied concomitantly, as positive and negative controls. At the time of entry into the study, strength of synchrony between the medial prefrontal cortex and nucleus accumbens (i.e. functional connectivity) was predictive (>80% accuracy) of individuals who subsequently transition to chronicity 1 year later. SUMMARY Properties of the brain's emotional learning circuitry predict the transition to chronic pain. The involvement of this circuitry in pain remains mostly unexplored. Future human and animal model studies are necessary to unravel underlying mechanisms driving pain chronicity, with the potential of advancing novel therapeutics for preventing pain chronification.
Collapse
|
15
|
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 2014; 12:866-85. [PMID: 24172334 DOI: 10.1038/nrd3893] [Citation(s) in RCA: 154] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Glycine transporters are endogenous regulators of the dual functions of glycine, which acts as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of neuronal excitation mediated by NMDA (N-methyl-D-aspartate) receptors at glutamatergic synapses. The two major subtypes of glycine transporters, GlyT1 and GlyT2, have been linked to the pathogenesis and/or treatment of central and peripheral nervous system disorders, including schizophrenia and related affective and cognitive disturbances, alcohol dependence, pain, epilepsy, breathing disorders and startle disease (also known as hyperekplexia). This Review examines the rationale for the therapeutic potential of GlyT1 and GlyT2 inhibition, and surveys the latest advances in the biology of glycine reuptake and transport as well as the drug discovery and clinical development of compounds that block glycine transporters.
Collapse
|
16
|
Zeilhofer HU, Benke D, Yevenes GE. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Annu Rev Pharmacol Toxicol 2012; 52:111-33. [PMID: 21854227 DOI: 10.1146/annurev-pharmtox-010611-134636] [Citation(s) in RCA: 116] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Potentially noxious stimuli are sensed by specialized nerve cells named nociceptors, which convey nociceptive signals from peripheral tissues to the central nervous system. The spinal dorsal horn and the trigeminal nucleus serve as first relay stations for incoming nociceptive signals. At these sites, nociceptor terminals contact a local neuronal network consisting of excitatory and inhibitory interneurons as well as of projection neurons. Blockade of neuronal inhibition in this network causes an increased sensitivity to noxious stimuli (hyperalgesia), painful sensations occurring after activation of non-nociceptive fibers (allodynia), and spontaneous pain felt in the absence of any sensory stimulation. It thus mimics the major characteristics of chronic pain states. Diminished inhibitory pain control in the spinal dorsal horn occurs naturally, e.g., through changes in the function of inhibitory neurotransmitter receptors or through altered chloride homeo-stasis in the course of inflammation or nerve damage. This review summarizes our current knowledge about endogenous mechanisms leading to diminished spinal pain control and discusses possible ways that could restore proper inhibition through facilitation of fast inhibitory neurotransmission.
Collapse
Affiliation(s)
- Hanns Ulrich Zeilhofer
- Institute of Pharmacology and Toxicology, University of Zurich, CH-8057 Zurich, Switzerland.
| | | | | |
Collapse
|
17
|
Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur Urol 2012; 62:704-12. [PMID: 22341128 DOI: 10.1016/j.eururo.2012.01.044] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2011] [Accepted: 01/24/2012] [Indexed: 12/26/2022]
Abstract
BACKGROUND Glycine is a major inhibitory neurotransmitter in the spinal cord, the concentration of which is regulated by two types of glycine transporters (GlyTs): GlyT1 and GlyT2. We hypothesized that the inhibition of GlyTs could ameliorate bladder overactivity and/or pain sensation in the lower urinary tract. OBJECTIVE Investigate the effects of GlyT inhibitors on bladder overactivity and pain behavior in rats. DESIGN, SETTING, AND PARTICIPANTS Cystometry was performed under urethane anesthesia in cyclophosphamide (CYP)-treated rats. In behavioral studies using conscious rats, nociceptive responses were induced by intravesical administration of resiniferatoxin (3μM). Selective GlyT1 or GlyT2 inhibitors were administered intrathecally to evaluate their effects. MEASUREMENTS Cystometric parameters, nociceptive behaviors (licking and freezing), and messenger RNA (mRNA) levels of GlyTs and glycine receptor (GlyR) subunits in the dorsal spinal cord (L6-S1) were measured. RESULTS AND LIMITATIONS During cystometry in CYP-treated rats, significant increases in intercontraction interval and micturition pressure threshold were elicited by ALX-1393, a selective GlyT2 inhibitor, but not by sarcosine, a GlyT1 inhibitor. These effects were completely reversed by strychnine, a GlyR antagonist. ALX-1393 also significantly suppressed nociceptive behaviors in a dose-dependent manner. In sham rats, GlyT2 mRNA was expressed at a much higher level (23-fold) in the dorsal spinal cord than GlyT1 mRNA. In CYP-treated rats, mRNA levels of GlyT2 and the GlyR α1 and β subunits were significantly reduced. CONCLUSIONS These results indicate that GlyT2 plays a major role in the clearance of extracellular glycine in the spinal cord and that GlyT2 inhibition leads to amelioration of CYP-induced bladder overactivity and pain behavior. GlyT2 may be a novel therapeutic target for the treatment of overactive bladder and/or bladder hypersensitive disorders such as bladder pain syndrome/interstitial cystitis.
Collapse
|
18
|
Giordano C, Cristino L, Luongo L, Siniscalco D, Petrosino S, Piscitelli F, Marabese I, Gatta L, Rossi F, Imperatore R, Palazzo E, de Novellis V, Di Marzo V, Maione S. TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception. ACTA ACUST UNITED AC 2011; 22:2495-518. [PMID: 22139792 DOI: 10.1093/cercor/bhr328] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
During neuropathic pain, caspases are activated in the limbic cortex. We investigated the role of TRPV1 channels and glial caspases in the mouse prelimbic and infralimbic (PL-IL) cortex after spared nerve injury (SNI). Reverse transcriptase-polymerase chain reaction, western blots, and immunfluorescence showed overexpression of several caspases in the PL-IL cortex 7 days postinjury. Caspase-3 release and upregulation of AMPA receptors in microglia, caspase-1 and IL-1β release in astrocytes, and upregulation of Il-1 receptor-1, TRPV1, and VGluT1 in glutamatergic neurons, were also observed. Of these alterations, only those in astrocytes persisted in SNI Trpv1(-/-) mice. A pan-caspase inhibitor, injected into the PL-IL cortex, reduced mechanical allodynia, this effect being reduced but not abolished in Trpv1(-/-) mice. Single-unit extracellular recordings in vivo following electrical stimulation of basolateral amygdala or application of pressure on the hind paw, showed increased excitatory pyramidal neuron activity in the SNI PL-IL cortex, which also contained higher levels of the endocannabinoid 2-arachidonoylglycerol. Intra-PL-IL cortex injection of mGluR5 and NMDA receptor antagonists and AMPA exacerbated, whereas TRPV1 and AMPA receptor antagonists and a CB(1) agonist inhibited, allodynia. We suggest that SNI triggers both TRPV1-dependent and independent glutamate- and caspase-mediated cross-talk among IL-PL cortex neurons and glia, which either participates or counteracts pain.
Collapse
Affiliation(s)
- Catia Giordano
- Endocannabinoid Research Group, Department of Experimental Medicine, Division of Pharmacology L. Donatelli, Second University of Naples, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
This article examines the present, and potential future, impact of brain imaging on chronic pain. It is argued that novel theories of chronic pain are coming to the fore, specifically through brain imaging of the human brain in chronic pain. Such studies show that the brain reorganizes in relation to chronic pain, in a pattern specific to the type of clinical pain, and that brain networks and receptor targets are being identified and reverse translated to animal studies of their efficacy and mechanisms. Future studies need to integrate across human brain imaging techniques, as well as more intensive reverse translational methods.
Collapse
Affiliation(s)
- A Vania Apkarian
- Northwestern University, Feinberg School of Medicine, Department of Physiology, 303 E Chicago Avenue, Chicago, IL 60610, USA
| |
Collapse
|
20
|
Role of different brain areas in peripheral nerve injury-induced neuropathic pain. Brain Res 2011; 1381:187-201. [DOI: 10.1016/j.brainres.2011.01.002] [Citation(s) in RCA: 98] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2010] [Revised: 12/16/2010] [Accepted: 01/03/2011] [Indexed: 02/07/2023]
|
21
|
Devoize L, Alvarez P, Monconduit L, Dallel R. Representation of dynamic mechanical allodynia in the ventral medial prefrontal cortex of trigeminal neuropathic rats. Eur J Pain 2011; 15:676-82. [PMID: 21316272 DOI: 10.1016/j.ejpain.2010.11.017] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2010] [Revised: 10/06/2010] [Accepted: 11/02/2010] [Indexed: 11/28/2022]
Abstract
Trigeminal neuropathic pain is due to lesion or dysfunction of the nervous system. Dynamic mechanical allodynia is a widespread symptom of neuropathic pain for which mechanisms are still poorly understood. Recent studies demonstrate that forebrain neurons, including neurons in the medial prefrontal cortex (mPFC) are important for the perception of acute and chronic pain. Using the phosphorylation of the extracellular-signal regulated kinase (pERK-1/2) as an anatomical marker of neuronal activation, the present study investigated how dynamic mechanical allodynia is processed in the rat ventral mPFC (prelimbic and infralimbic cortex) after chronic constriction injury to the infraorbital nerve (IoN-CCI). Two weeks after unilateral IoN-CCI, rats showed a dramatic bilateral trigeminal dynamic mechanical allodynia. Light, moving stroking of the infraorbital skin resulted in strong, bilateral upregulation of pERK-1/2 in the ventral mPFC of IoN-CCI animals. pERK-1/2 was located in neuronal cells only. Stimulus-evoked pERK-1/2 immunopositive cell bodies displayed a rostrocaudal gradient and layer-selective distribution in the ventral mPFC, being predominant in the rostral ventral mPFC and in layers II-III and V-VI of the ventral mPFC. In layers II-III, intense pERK-1/2 also extended into distal dendrites, up to layer I. These results demonstrate that trigeminal nerve injury induces a significant alteration in the ventral mPFC processing of tactile stimuli and suggest that ERK phosphorylation contributes to the mechanisms underlying abnormal pain perception under this condition.
Collapse
Affiliation(s)
- Laurent Devoize
- Clermont Université, Université d'Auvergne, Neurobiologie de douleur trigémiale, BP 10448, F-63000 Clermont-Ferrand, France
| | | | | | | |
Collapse
|
22
|
Parks EL, Geha PY, Baliki MN, Katz J, Schnitzer TJ, Apkarian AV. Brain activity for chronic knee osteoarthritis: dissociating evoked pain from spontaneous pain. Eur J Pain 2011; 15:843.e1-14. [PMID: 21315627 DOI: 10.1016/j.ejpain.2010.12.007] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Revised: 11/24/2010] [Accepted: 12/20/2010] [Indexed: 01/15/2023]
Abstract
Chronic pain is a hallmark of osteoarthritis (OA), yet little is known about its properties and representation in the brain. Here we use fMRI combined with psychophysics to study knee pain in fourteen OA patients and nine healthy controls. Mechanical painful pressure stimuli were applied to the knee in both groups and ratings of evoked pain and related brain activity examined. We observe that psychophysical properties and brain activation patterns of evoked pain are essentially the same between OA patients and healthy subjects, and between worse and better OA knees. In OA patients, stimulus-related brain activity could be distinguished from brain activity associated with spontaneous pain. The former activated brain regions commonly observed for acute painful stimuli in healthy subjects, while the spontaneous pain of OA engaged prefrontal-limbic regions closely corresponding to areas observed for spontaneous pain in other chronic pain conditions, such as chronic back pain and post-herpetic neuralgia. Arthritis-related clinical characteristics of knee OA also mapped to prefrontal-limbic regions. In a subgroup of patients (n=6) we examined brain activity changes for a 2-week, repeat measure, cyclooxygenase-2 inhibitor (valdecoxib) therapy. Treatment decreased spontaneous pain for the worse knee and clinical characteristics of OA, and increased blood and csf levels of the drug which correlated positively with prefrontal-limbic brain activity. These findings indicate dissociation between mechanically induced and spontaneous OA knee pain, the latter engaging brain regions involved in emotional assessment of the self, and challenge the standard clinical view regarding the nature of OA pain.
Collapse
Affiliation(s)
- Elle L Parks
- Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
| | | | | | | | | | | |
Collapse
|
23
|
Apkarian VA, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2010; 152:S49-S64. [PMID: 21146929 DOI: 10.1016/j.pain.2010.11.010] [Citation(s) in RCA: 492] [Impact Index Per Article: 35.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Accepted: 11/09/2010] [Indexed: 12/23/2022]
Affiliation(s)
- Vania A Apkarian
- Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA Departments of Anesthesia and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
| | | | | |
Collapse
|